Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.

Details

Ressource 1Download: BIB_188C15EE0182.P001.pdf (146.25 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_188C15EE0182
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.
Journal
British Journal of Cancer
Author(s)
De Bernardi B., Mosseri V., Rubie H., Castel V., Foot A., Ladenstein R., Laureys G., Beck-Popovic M., de Lacerda A.F., Pearson A.D., De Kraker J., Ambros P.F., de Rycke Y., Conte M., Bruzzi P., Michon J.
ISSN
0007-0920
Publication state
Published
Issued date
2008
Peer-reviewed
Oui
Volume
99
Number
7
Pages
1027-1033
Language
english
Abstract
Main objective of this study was to confirm that surgery alone is an effective and safe treatment for localised resectable neuroblastoma except stage 2 with amplified MYCN gene (MYCNA). Of 427 eligible stages 1-2 patients, 411 had normal MYCN and 16 had MYCNA. Of the 288 stage 1 patients with normal MYCN, 1 died of complications and 16 relapsed, 2 of whom died; 5-year relapse-free survival (RFS) and overall survival (OS) rates were 94.3% (95% confidence interval (CI): 91.6-97) and 98.9% (95% CI: 97.7-100), respectively. Of the 123 stage 2 patients with normal MYCN, 1 died of sepsis and 22 relapsed, 8 of whom died (RFS 82.8%, 95% CI: 76.2-89.5; OS 93.2%, 95% CI: 88.7-97.8). In stage 2, OS and RFS were worse for patients with elevated LDH and unfavourable histopathology. Of 16 children with MYCNA, 7 were stage 1 (5 relapses and 4 deaths) and 9 were stage 2 (3 relapses and 2 deaths) patients. In conclusion, surgery alone yielded excellent OS for both stage 1 and 2 neuroblastoma without MYCNA, although stage 2 patients with unfavourable histopathology and elevated LDH suffered a high number of relapses. Both stage 1 and 2 patients with MYCNA were at greater risk of relapse.
Keywords
Disease Progression, Disease-Free Survival, Europe, Female, Genes, myc, Humans, Infant, Infant, Newborn, Male, Neuroblastoma/genetics, Neuroblastoma/surgery, Prognosis, Recurrence, Survival Rate
Pubmed
Web of science
Open Access
Yes
Create date
15/10/2009 7:54
Last modification date
20/08/2019 12:49
Usage data